Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A

Abstract

Several case reports and uncontrolled trials have established the use of cyclosporine A (CsA) in systemic lupus erythematosus (SLE) but some concerns have been raised because of its kidney damaging effects. We here report the results of a retrospective follow-up study designed to assess the safety profile and causes of discontinuation due to adverse events in SLE patients treated with CsA.

We treated 56 SLE patients with oral CsA at doses of 3 ± 5 mg/kg for an average of 26 months. Adverse events not leading to the discontinuation of therapy were observed in 62.5% of the patients, the most frequent being hypertrichosis. CsA was stopped because of the occurrence of side effects in 9=56 (16%) of the patients. The most common were nephrotoxicity (3=9) and the occurrence of tremors (3=9). These effects were always reversible within three months of CsA withdrawal. The patients who were older than 40 y had a significant slightly increased risk of stopping CsA therapy for any adverse events (RR 1.08; CI 95% 1.03 ± 1.14).

In comparison with previous studies, this study involved a larger cohort of SLE patients who were evaluated for a longer period of follow-up, and confirmed the good tolerability of CsA in these subjects.

Keywords

cyclosporine A systemic lupus erythematosus safety profile adverse events

Get full access to this article

View all access options for this article.

References

Diasio RB , Lo Buglio AF . Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman JG (ed). Goodman E and Gilman's The Pharmacological Basis of Therapeutics, 9th edn, Vol. 52. McGraw-Hill: New York , 1996, pp 1291–1308.

Feutren G . The optimal use of Cyclosporine A in autoimmune disease . J Autoimmun 1992; 5(Suppl A): 183–195 .

Miescher PA , Beris P . Immunosuppressive therapy in the treatment of autoimmune disease . Springer Semin Immunopathol 1984; 7: 69–90 .

Favre H , Miescher PA , Huang YP et al. Cyclosporin in the treatment of lupus nephritis . Am J Nephrol 1989; 9(Suppl 1): 57–60 .

Caccavo D , Lagana Á B , Mitterhofer A et al. Long term treatment of systemic lupus erythematosus with cyclosporine A . Arthritis Rheum 1997; 40: 27–35 .

Feutren G , Querin S , Tron F et al. The effects of cyclosporine in patients with systemic lupus . Transplant Proc 1986; 18: 643–644 .

Dammacco F , Rizzi R , Ferraccioli GF et al. Effect of low dose cyclosporine A in association with corticosteroids vs corticosteroids alone on SLE disease activity: 12-month results of a randomized pilot study . Clin Immunol Immunopathol 1995; 75: 278-278 (abstract 101).

Manger K , Kalden JR , Manger B . Cyclosporine A in the treatment of systemic lupus erythematosus: results of an open clinical study . Br J Rheum 1996; 35: 669–675 .

Dostal C , Tesar V , Rychlik I et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study . Lupus 1998; 7: 29–36 .

10.

Feutren G , Abeywickrama K , Friend D et al. Predictive value of cyclosporine A levels for efficacy on renal dysfunction in psoriasis . Br J Dermatol 1990; 122(Suppl 36): 57–69 .

11.

Dieterle A , Aberywickrama K , von Graffenried B . Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporin . Transplant Proc 1998; 20(Suppl 4): 349–355 .

12.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 380–391 .

13.

Olivieri I , Salvarani C , Cantini F et al. Therapy with cyclosporine in psoriatic arthritis . Semin Arthritis Rheum 1997; 27: 36–43 .

14.

Dijkmans BA , van Rijthoven AW , Goei The HS et al. Cyclosporin in rheumatoid arthritis . Semin Arthritis Rheum 1992; 22: 30–36 .

15.

Isenberg DA , Snaith ML , Al-Khader AA et al. Cyclosporin relieves arthralgia, causes angioedema . New Engl J Med 1980; 303: 754-754 (letter).

16.

Isenberg DA , Snaith ML , Morrow WJ et al. Cyclosporine A for treatment of systemic lupus erythematosus . Int J Immunopharmacol 1981; 3: 163–169 .

17.

Deteix P , Lefrancois N , Lavile M et al. Open therapeutic trial of cyclosporin in systemic lupus erythematosus. Preliminary results in four patients. In: Schindler R (ed). Cyclosporin in Autoimmune Disease. Springer: Berlin , 1985, pp 361–365.

18.

Feutren G , Querin S , Noel LH et al. Effects of cyclosporin in severe systemic lupus erythematosus . J Pediatr 1987; 111: 1063–1068 .

19.

Miescher PA , Favre H , Mihatsch MJ et al. The place of cyclosporine A in the treatment of connective tissue disease . Transplant Proc 1988; 20(Suppl 4): 224–237 .

20.

Pasero G , Priolo F , Marubini E et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporine A . Arthritis Rheum 1996; 39: 1006–1015 .

21.

Tokuda M , Kurata N , Mizoguchi A et al. Effect of low-dose cyclosporine A on systemic lupus erythematosus disease activity . Arthritis Rheum 1994; 37: 551–558 .

22.

Radhakrishnan J , Kunis CL , Appel G . Cyclosporine treatment of lupus membranous nephropathy . Clin Nephrol 1994; 42: 147–154 .